The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Self-administration of anti-CD38 antibodies in multiple myeloma treatment
Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, provides insight into self-administration of anti-CD38 antibodies in multiple myeloma treatment, highlighting that both daratumumab and isatuximab are now available in subcutaneous formulations that can be self-administered by patients, allowing for greater flexibility and convenience. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the anti-CD38 antibodies, daratumumab and isatuximab, are widely used for myeloma patients. And these were initially given intravenously and have then been studied as subcutaneous formulations for administration as well. And importantly, that has always previously been done within a hospital setting. Or for daratumumab, there was a study looking at the administration, for example, of daratumumab in the home setting, but by a healthcare professional...
So the anti-CD38 antibodies, daratumumab and isatuximab, are widely used for myeloma patients. And these were initially given intravenously and have then been studied as subcutaneous formulations for administration as well. And importantly, that has always previously been done within a hospital setting. Or for daratumumab, there was a study looking at the administration, for example, of daratumumab in the home setting, but by a healthcare professional. More recently, and really importantly, both of these drugs are now able to be delivered by the patient themselves as a self-administered approach, which means that they don’t need to rely on a specific time for a healthcare professional to come and administer the dose. For example, for daratumumab, which was approved for self-administration by the EMA, the patient can be trained to deliver their subcutaneous daratumumab after they’ve had the first four doses within a hospital setting. They can then learn how to do it themselves and take the doses home with them to be delivered at home at a time that’s convenient for them, obviously still under the supervision of their doctor and with regular reviews. For isatuximab, the other anti-CD38 antibody, they’ve developed the subcutaneous formulation into an on-body device which helps with the administration and again can be delivered by the patient themselves.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
